Reata Pharmaceuticals (NASDAQ:RETA) and TapImmune (NASDAQ:MRKR) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their profitability, risk, institutional ownership, earnings, valuation, dividends and analyst recommendations.
This table compares Reata Pharmaceuticals and TapImmune’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
This is a breakdown of recent ratings and target prices for Reata Pharmaceuticals and TapImmune, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Reata Pharmaceuticals currently has a consensus price target of $130.80, indicating a potential upside of 50.05%. TapImmune has a consensus price target of $10.90, indicating a potential upside of 72.23%. Given TapImmune’s stronger consensus rating and higher probable upside, analysts plainly believe TapImmune is more favorable than Reata Pharmaceuticals.
Earnings & Valuation
This table compares Reata Pharmaceuticals and TapImmune’s revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Reata Pharmaceuticals||$53.59 million||48.90||-$80.55 million||($2.87)||-30.37|
Reata Pharmaceuticals has higher revenue and earnings than TapImmune. Reata Pharmaceuticals is trading at a lower price-to-earnings ratio than TapImmune, indicating that it is currently the more affordable of the two stocks.
Institutional and Insider Ownership
54.4% of Reata Pharmaceuticals shares are owned by institutional investors. Comparatively, 33.6% of TapImmune shares are owned by institutional investors. 34.4% of Reata Pharmaceuticals shares are owned by company insiders. Comparatively, 23.7% of TapImmune shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Volatility and Risk
Reata Pharmaceuticals has a beta of 2.32, suggesting that its stock price is 132% more volatile than the S&P 500. Comparatively, TapImmune has a beta of 0.34, suggesting that its stock price is 66% less volatile than the S&P 500.
About Reata Pharmaceuticals
Reata Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops novel therapeutics for patients with serious or life-threatening diseases by targeting molecular pathways that regulate cellular metabolism and inflammation. The company is developing Phase III clinical trial programs, including bardoxolone methyl (Bard) for the treatment of patients with chronic kidney disease caused by Alport syndrome, as well as for a form of pulmonary arterial hypertension associated with connective tissue disease; and omaveloxolone that is Phase II clinical trial for the treatment of patients with Friedreich's ataxia It is also developing RTA 901, which completed Phase 1 clinical trials for the treatment of orphan neurological indications; and RORgT Inhibitors that are in the preclinical development phase for the potential treatment of a range of autoimmune, inflammatory, and fibrotic diseases. Reata Pharmaceuticals, Inc. has a strategic collaboration agreement with Kyowa Hakko Kirin Co., Ltd. to develop and commercialize Bard for renal, cardiovascular, diabetes, and various other related metabolic indications in Japan, China, Hong Kong, Macao, South Korea, Taiwan, Thailand, Singapore, the Philippines, Malaysia, Indonesia, Brunei, Vietnam, Laos, Myanmar, and Cambodia; and AbbVie Inc. to jointly research, develop, and commercialize all second- and later-generation Nrf2 activators for all indications other than renal, cardiovascular, and metabolic indications. The company was formerly known as Reata Discovery, Inc. and changed its name to Reata Pharmaceuticals, Inc. in May 2005. Reata Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Irving, Texas.
Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, develops and commercializes novel cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. Its MultiTAA T cell technology is based on the tumor-specific T cells that recognize tumor associated antigens and kill tumor cells expressing those targets. The company is developing TPIV100/110, which is in Phase II clinical trial to treat human epidermal growth factor receptor 2 breast cancer; and TPIV200 that is in Phase II clinical trial for the treatment of breast and ovarian cancers. It is also developing a proprietary nucleic acid-based antigen expression technology, PolyStart, to improve the ability of the immune system to recognize and destroy diseased cells. The company is headquartered in Houston, Texas.
Receive News & Ratings for Reata Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Reata Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.